FDA to Hold Public Hearing on Psychedelic Therapies as Federal Push Accelerates

The U.S. Food and Drug Administration will convene a public hearing on Monday to collect feedback on the therapeutic potential of psychedelic drugs, the latest move in a months-long federal effort to accelerate development of such treatments for serious mental illnesses.

The push traces back to April, when President Donald Trump directed the FDA to prioritise psychedelic drug programmes under its priority-voucher scheme. The same order asked the agency to work with the Drug Enforcement Administration on a pathway for some patients to access investigational treatments through the federal Right to Try law, which lets certain seriously ill patients seek experimental therapies, and to deepen collaboration with the Department of Veterans Affairs.

Three companies developing psychedelic-based treatments have since received priority vouchers — one for psilocybin for treatment-resistant depression, another for psilocybin for major depressive disorder, and a third for methylone for post-traumatic stress disorder.

Monday's hearing is expected to focus on practical questions that could shape how these therapies are tested and delivered: provider training and credentials, patient screening and monitoring, access and reimbursement, clinic capacity, and the collection of long-term safety data. The agency has said it is not seeking views on individual drug applications, the scheduling of controlled substances, or the legalisation of psychedelics.

Robert Barrow, chief executive of Definium Therapeutics, which is developing an LSD-based therapy, said the hearing offers a useful opportunity for continued public dialogue among regulators, clinicians and patients. He argued that psychedelics should be handled like conventional drug development, science and medicine rather than treated as an unusually novel category requiring special rules.

Days before the hearing, senior FDA officials, including Michael Davis, acting head of the agency's Center for Drug Evaluation and Research, published a paper in the New England Journal of Medicine setting out a framework for developing and approving psychedelic drugs. The officials wrote that the agency was "meeting this moment" on hard-to-treat conditions such as major depressive disorder and PTSD.

Analysts at Jefferies said the framework signalled the FDA's willingness to consider flexible trial designs to address challenges such as "functional unblinding," in which a drug's noticeable psychoactive effects reveal to participants which treatment they received. The agency has indicated that developers could use questionnaires, blinded central raters and, in some studies, lower doses or active comparators that mimic mild psychological effects to help tackle the problem.

The administration's backing has renewed investor interest in the sector. Industry executives say it could improve coordination between the FDA and the DEA and help reduce regulatory delays, though researchers caution that approved treatments remain likely years away. Analysts said continued alignment among regulators, clinicians and developers on a safe, supervised rollout should benefit AtaiBeckley, Compass Pathways, Definium Therapeutics, Helus Pharma and GH Research.